Unicycive Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDUnicycive Therapeutics, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is weak (RS Rating: 31), showing significant lag compared to the market leaders. Earnings contraction of 8% provides fundamental context to the price action. Investors should exercise caution due to high volatility (79% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $6.90 | -21.34% | BELOW |
| 50 SMA | $7.36 | -26.21% | BELOW |
| 100 SMA | $7.06 | -23.08% | BELOW |
| 150 SMA | $6.78 | -19.95% | BELOW |
| 200 SMA | $6.28 | -13.58% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is UNCY in an uptrend right now?
UNCY has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is UNCY overbought or oversold?
UNCY's RSI (14) is 39. The stock is in neutral territory, neither overbought nor oversold.
Is UNCY outperforming the market?
UNCY has a Relative Strength (RS) Rating of 31 out of 99. UNCY is currently lagging the broader market.
Where is UNCY in its 52-week range?
UNCY is trading at $5.43, which is 62% of its 52-week high ($8.74) and 34% above its 52-week low ($3.71).
How volatile is UNCY?
UNCY has a Beta of 1.05 and 52-week volatility of 79%. It's more volatile than the S&P 500 - expect bigger swings.